Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. The company's product candidate FAK inhibitor, VS-6063, is in Phase 1 study in combination with PD-1 inhibitor pembrolizumab and gemcitabine for pancreatic cancer; a Phase Ib clinical trial in combination with paclitaxel for patients with ovarian cancer; a Phase II study in patients with non-small cell lung cancer; a Phase II trial preceding surgery in mesothelioma; and a Phase 1/1b clinical trail in combination with avelumab in patients with ovarian cancer, as well as a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma. It is also developing FAK inhibitor, VS-4718 that is in Phase 1, single-agent, dose escalation trial in patients with advanced cancers; and a Phase 1, dose-escalation clinical trial in combination with gemcitabine and nab-paclitaxel in patients with advanced solid tumors, as well as a Phase 1, dose-escalation clinical trial of PI3K/mTORC1/2 inhibitor, VS-5584, in patients with advanced non-hematologic malignancies or lymphoma. The company has license agreement with Whitehead Institute for Biomedical Research; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is based in Needham, Massachusetts.
http://www.priceseries.com/trade/VSTM-Verastem-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2020040620200427.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments